FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

NEXT STORY
Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option
PREV STORY
Penns Woods Bancorp, Inc. Reports Third Quarter 2021 Earnings
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

athenahealth Marketplace Partners Save Providers Time, Money and Reduce Work Burden

WATERTOWN, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ:ATHN), a leading provider ...

author_avatar
NASDAQ Market News

Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED ...

author_avatar
NASDAQ Market News

Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology

NEW HAVEN, Conn., April 03, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ...

author_avatar
NASDAQ Market News